Capital Research Global Investors 13D and 13G filings for Ultragenyx Pharmaceutical Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-10-08 2:08 pm Sale |
2021-10-12 | 13G | Ultragenyx Pharmaceutical Inc. RARE |
Capital Research Global Investors | 3,361,792 5.000% |
-3,900,109 (-53.71%) |
Filing |
| 2021-02-16 1:16 pm Purchase |
2021-02-16 | 13G | Ultragenyx Pharmaceutical Inc. RARE |
Capital Research Global Investors | 7,261,901 11.000% |
899,206 (+14.13%) |
Filing |